Protocol Ledger

NCT05678270 · Phase II · RECRUITING

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Interventional Phase II clinical trial protocol NCT05678270 sponsored by Beijing InnoCare Pharma Tech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-15 Enrollment: 70 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05678270
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05678270
Protocol FieldVerified Registry Value
NCT IdentifierNCT05678270
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment70 participants (ESTIMATED)
Registered Start Date2022-11-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI